Eli Lilly and Company has become a key player in the production of tirzepatide, a groundbreaking treatment for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, demonstrates significant ability to improve glycemic control and reduce the risk of cardiovascular disease. The sophisticated synthesis of tirzepatide requires a series o